Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A user noticed watery semen and decreased volume after a week of using finasteride and asked if taking Zinc, pygeum, and lecithin supplements would affect finasteride's effectiveness. The conversation is about the side effects of finasteride and potential supplements to counteract them.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

The conversation is about using liposomal finasteride for hair loss treatment, highlighting its cost-effectiveness and ease of preparation. It suggests using lecithin and crushed finasteride pills to make the solution, which has shown to be significantly more effective than other topical formulations.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

The conversation is about a user experiencing hair thinning and considering exosome treatment after being advised against a hair transplant. The user seeks advice from others who may have tried exosomes for hair loss.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Exosomes are being considered for hair regrowth after using finasteride and minoxidil, with skepticism about their effectiveness and high cost. Users discuss administration methods like injections and microneedling, but concerns about pricing and potential scams are prevalent.

The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.

Applying vitamin E capsules, specifically tocotrienols, on the scalp for hair regrowth. Users are skeptical about its effectiveness due to lack of evidence.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

The conversation discusses treatments for a receding hairline, specifically comparing microneedling with exosomes to injecting them. The user seeks recommendations for beginner-friendly resources, such as YouTube videos, to help start these treatments.

User seeks Procyanidin B2 supplement source and asks for dosage comparison. Another user requests study details and apple type importance.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.